Smart-Money SignalNeutral · 46/100— Insiders are net sellers over 90 days (-$496K, 7 sales vs 2 buys)
Net Income-$17.8M
EPS$-0.31
Market Cap$225.7M
Price Performance
Historical data including institutional events
Company Profile
J
Jesse Shefferman
CEO & Executive Director
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
The companyâs lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids.
The company is headquartered in New York, New York.
